[144] Avidity Biosciences, Inc. SEC Filing
Avidity Biosciences (RNA) filed a Form 144 reporting the proposed sale of 25,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $1,195,500. The filing shows the shares were acquired and paid for on 08/28/2025 via exercise of stock options from the issuer, and the filer reports no securities sold in the past three months. The notice includes the filer鈥檚 representation that they are not aware of undisclosed material adverse information and contains the standard signature and certification language.
Avidity Biosciences (RNA) ha presentato un Modulo 144 segnalando la proposta vendita di 25.000 azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASDAQ per un valore di mercato complessivo di 1.195.500 dollari. La comunicazione indica che le azioni sono state acquistate e pagate il 08/28/2025 tramite l鈥檈sercizio di opzioni su azioni concesse dall鈥檈mittente; il dichiarante segnala di non aver venduto titoli nei tre mesi precedenti. L鈥檃vviso riporta inoltre la dichiarazione del dichiarante di non essere a conoscenza di informazioni materiali avverse non divulgate e include il consueto linguaggio di firma e certificazione.
Avidity Biosciences (RNA) present贸 un Formulario 144 notificando la propuesta venta de 25.000 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney LLC en NASDAQ, por un valor de mercado agregado de 1.195.500 d贸lares. El documento indica que las acciones fueron adquiridas y pagadas el 08/28/2025 mediante el ejercicio de opciones sobre acciones emitidas por la sociedad; el declarante informa no haber vendido valores en los 煤ltimos tres meses. El aviso incluye adem谩s la manifestaci贸n del declarante de no tener conocimiento de informaci贸n adversa material no divulgada y contiene el lenguaje est谩ndar de firma y certificaci贸n.
Avidity Biosciences(RNA)電� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 氤错喌欤� 25,000欤茧ゼ 齑� 鞁滌灔臧�旃� 1,195,500雼煬鞐� 毵る弰頃� 鞓堨爼鞛勳潉 氤搓碃頃橂姅 靹滌嫕 144毳� 鞝滌稖頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 頃措嫻 欤检嫕鞚� 2025-08-28鞐� 氚滍枆須岇偓鞚� 鞀ろ啞鞓奠厴 頄夓偓搿� 旆摑路雽�旮堨旮夒悩鞐堨溂氅�, 鞝滌稖鞚胳潃 歆�雮� 3臧滌洈 霃欖晥 歃濌秾鞚� 毵り皝頃� 氚� 鞐嗠嫟瓿� 氤搓碃頃橁碃 鞛堨姷雼堧嫟. 瓿奠鞐愲姅 鞝滌稖鞚胳澊 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞚胳頃橁碃 鞛堨 鞎婋嫟電� 歆勳垹瓿� 響滌 靹滊獏 氚� 鞚胳 氍戈惮臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Avidity Biosciences (RNA) a d茅pos茅 un formulaire 144 d茅clarant la cession projet茅e de 25 000 actions ordinaires via Morgan Stanley Smith Barney LLC sur le NASDAQ pour une valeur de march茅 totale de 1 195 500 dollars. Le dossier pr茅cise que les actions ont 茅t茅 acquises et pay茅es le 08/28/2025 par l鈥檈xercice d鈥檕ptions sur actions 茅mises par la soci茅t茅 ; le d茅clarant indique n鈥檃voir vendu aucun titre au cours des trois derniers mois. L鈥檃vis comprend 茅galement la d茅claration du d茅clarant selon laquelle il n鈥檃 pas connaissance d鈥檌nformations d茅favorables mat茅rielles non divulgu茅es et contient le libell茅 standard de signature et de certification.
Avidity Biosciences (RNA) hat ein Formular 144 eingereicht, in dem der beabsichtigte Verkauf von 25.000 Stammaktien 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ mit einem Gesamtmarktwert von 1.195.500 US-Dollar gemeldet wird. Die Einreichung gibt an, dass die Aktien am 08/28/2025 durch Aus眉bung von Aktienoptionen des Emittenten erworben und bezahlt wurden; der Meldende gibt an, in den vergangenen drei Monaten keine Wertpapiere verkauft zu haben. Die Mitteilung enth盲lt zudem die Erkl盲rung des Meldenden, dass ihm keine nicht offengelegten wesentlich nachteiligen Informationen bekannt sind, sowie die 眉blichen Unterschrifts- und Zertifizierungsformulierungen.
- Filed under Rule 144 with broker details and transaction specifics
- Securities were acquired via exercise of stock options with cash payment on 08/28/2025
- No other securities sold by the filer in the past three months
- Filer includes required certification regarding material nonpublic information
- None.
Insights
TL;DR: Small, routine insider-option exercise and proposed sale; appears procedural and compliant with Rule 144.
The filing documents an insider exercise of stock options and a contemporaneous proposed sale of 25,000 shares valued at $1,195,500 brokered through Morgan Stanley Smith Barney LLC on NASDAQ. The acquisition and payment date are the same (08/28/2025), indicating the shares stem from option exercise rather than a prior secondary purchase. The filer reports no other sales in the last three months, and the filing includes the required attestations about material nonpublic information. Given the size relative to total outstanding shares (128,653,337), this appears to be a routine compliance notice rather than a material corporate event.
TL;DR: Filing meets disclosure requirements; includes standard representations and broker details, supporting transparency.
The Form 144 supplies the broker name and address, exact share count, aggregate market value, outstanding share count, and acquisition mechanics (exercise of stock options, cash payment). It also includes the filer鈥檚 certification regarding undisclosed material adverse information. These elements satisfy typical Rule 144 disclosure expectations and provide investors and regulators with necessary transaction detail for oversight.
Avidity Biosciences (RNA) ha presentato un Modulo 144 segnalando la proposta vendita di 25.000 azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASDAQ per un valore di mercato complessivo di 1.195.500 dollari. La comunicazione indica che le azioni sono state acquistate e pagate il 08/28/2025 tramite l鈥檈sercizio di opzioni su azioni concesse dall鈥檈mittente; il dichiarante segnala di non aver venduto titoli nei tre mesi precedenti. L鈥檃vviso riporta inoltre la dichiarazione del dichiarante di non essere a conoscenza di informazioni materiali avverse non divulgate e include il consueto linguaggio di firma e certificazione.
Avidity Biosciences (RNA) present贸 un Formulario 144 notificando la propuesta venta de 25.000 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney LLC en NASDAQ, por un valor de mercado agregado de 1.195.500 d贸lares. El documento indica que las acciones fueron adquiridas y pagadas el 08/28/2025 mediante el ejercicio de opciones sobre acciones emitidas por la sociedad; el declarante informa no haber vendido valores en los 煤ltimos tres meses. El aviso incluye adem谩s la manifestaci贸n del declarante de no tener conocimiento de informaci贸n adversa material no divulgada y contiene el lenguaje est谩ndar de firma y certificaci贸n.
Avidity Biosciences(RNA)電� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 氤错喌欤� 25,000欤茧ゼ 齑� 鞁滌灔臧�旃� 1,195,500雼煬鞐� 毵る弰頃� 鞓堨爼鞛勳潉 氤搓碃頃橂姅 靹滌嫕 144毳� 鞝滌稖頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 頃措嫻 欤检嫕鞚� 2025-08-28鞐� 氚滍枆須岇偓鞚� 鞀ろ啞鞓奠厴 頄夓偓搿� 旆摑路雽�旮堨旮夒悩鞐堨溂氅�, 鞝滌稖鞚胳潃 歆�雮� 3臧滌洈 霃欖晥 歃濌秾鞚� 毵り皝頃� 氚� 鞐嗠嫟瓿� 氤搓碃頃橁碃 鞛堨姷雼堧嫟. 瓿奠鞐愲姅 鞝滌稖鞚胳澊 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞚胳頃橁碃 鞛堨 鞎婋嫟電� 歆勳垹瓿� 響滌 靹滊獏 氚� 鞚胳 氍戈惮臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Avidity Biosciences (RNA) a d茅pos茅 un formulaire 144 d茅clarant la cession projet茅e de 25 000 actions ordinaires via Morgan Stanley Smith Barney LLC sur le NASDAQ pour une valeur de march茅 totale de 1 195 500 dollars. Le dossier pr茅cise que les actions ont 茅t茅 acquises et pay茅es le 08/28/2025 par l鈥檈xercice d鈥檕ptions sur actions 茅mises par la soci茅t茅 ; le d茅clarant indique n鈥檃voir vendu aucun titre au cours des trois derniers mois. L鈥檃vis comprend 茅galement la d茅claration du d茅clarant selon laquelle il n鈥檃 pas connaissance d鈥檌nformations d茅favorables mat茅rielles non divulgu茅es et contient le libell茅 standard de signature et de certification.
Avidity Biosciences (RNA) hat ein Formular 144 eingereicht, in dem der beabsichtigte Verkauf von 25.000 Stammaktien 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ mit einem Gesamtmarktwert von 1.195.500 US-Dollar gemeldet wird. Die Einreichung gibt an, dass die Aktien am 08/28/2025 durch Aus眉bung von Aktienoptionen des Emittenten erworben und bezahlt wurden; der Meldende gibt an, in den vergangenen drei Monaten keine Wertpapiere verkauft zu haben. Die Mitteilung enth盲lt zudem die Erkl盲rung des Meldenden, dass ihm keine nicht offengelegten wesentlich nachteiligen Informationen bekannt sind, sowie die 眉blichen Unterschrifts- und Zertifizierungsformulierungen.
FAQ
What did Avidity Biosciences (RNA) report on this Form 144?
How were the 25,000 shares acquired according to the Form 144?
Does the filing show any other sales by the filer in the past three months?
Which broker is handling the proposed sale?
What is the total number of Avidity Biosciences shares outstanding reported in the filing?
